Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-47357

Andus, T; Kocjan, A; Müser, M; Baranovsky, A; Mikhailova, T L; Zvyagintseva, T D; Dorofeyev, A E; Lozynskyy, Y S; Cascorbi, I; Stolte, M; Vieth, M; Dilger, K; Mohrbacher, R; Greinwald, R (2010). Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflammatory Bowel Diseases, 16(11):1947-1956.

[img] PDF - Registered users only
1MB

Abstract

BACKGROUND: Mesalamine suppositories are first-line therapy in active ulcerative proctitis; the standard regime still recommends multiple doses per day. The primary objective of this study was to show the noninferiority of once-daily administration of a novel 1 g mesalamine suppository versus thrice-daily administration of the 0.5 g mesalamine suppository.

METHODS: This was a single-blind (investigator-blinded), randomized, multicenter, comparative, Phase III clinical trial. Patients with mild to moderately active ulcerative proctitis inserted either one mesalamine 1 g suppository at bedtime or one mesalamine 0.5 g suppository thrice daily over a 6-week period. The primary endpoint was rate of remission (Disease Activity Index below 4).

RESULTS: In all, 354 patients were evaluable for safety and per-protocol analysis. The new regimen demonstrated noninferiority: The percentage of patients with remission was 87.9% for the once-daily 1 g mesalamine suppository and 90.7% for the thrice-daily 0.5 g mesalamine suppository. Each regimen resulted in prompt cessation of clinical symptoms (e.g., median time to ≤3 stools per day (all without blood): 5 days in the 1 g mesalamine once-daily and 7 days in the 0.5 g mesalamine thrice-daily group). Patients preferred applying suppositories once a day.

CONCLUSIONS: In active ulcerative proctitis the once-daily administration of a 1 g mesalamine suppository is as effective and safe, yet considerably more convenient, than the standard thrice-daily administration of a 0.5 g mesalamine suppository.

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Gastroenterology and Hepatology
DDC:610 Medicine & health
Date:2010
Deposited On:03 Mar 2011 19:06
Last Modified:27 Nov 2013 19:53
Publisher:Wiley-Blackwell
ISSN:1078-0998
Publisher DOI:10.1002/ibd.21258
PubMed ID:20310020
Citations:Web of Science®. Times Cited: 8
Google Scholar™
Scopus®. Citation Count: 9

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page